Background: Cardiovascular diseases (CVDs) pose a significant global health concern and are the most common cause of death and disability, necessitating preventive interventions targeting modifiable risk factors. Recently, mobile-health technology has been developed to improve the delivery of cardiovascular prevention by risk factor modification. The "Green Heart" mobile application (app) was designed to aid in risk factor control among coronary artery disease (CAD) patients.
Methods: This parallel-group, single-blinded randomized controlled trial enrolled 1590 CAD patients, including 668 current smokers, randomly assigned to control (paper-based education) and intervention (application-based) groups. The app encompassed three modules targeting smoking cessation, dyslipidemia control, and blood pressure management. This study evaluated the impact of the smoking cessation module on behavioral change among current smokers. Green Heart assesses nicotine dependence, offering personalized quit plans, educational content, motivational messages, and automated progress tracking. The odds of smoking behavior changes during the 24-week follow-up underwent assessment.
Results: The intention-to-treat analysis highlighted significantly elevated rates of smoking cessation and reductions in the intervention group versus the control group. Adherence to the app (per-treatment analysis) also demonstrated significantly more favorable smoking behavior changes among the application users. Logistic regression emphasized higher odds of quitting and reduction in smoking in the application group, showing an odds ratio of 2.14 (95% CI: 1.16-3.97) compared to those not using the app (=0.015).
Conclusion: Our results confirmed that complete adherence to the app for at least 24 weeks was linked to alterations in cigarette smoking behavior among CAD patients. IRCT20221016056204N1.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11097320 | PMC |
http://dx.doi.org/10.34172/aim.2024.37 | DOI Listing |
Alzheimers Dement
December 2024
University of California, San Francisco, and San Francisco VA Health Care System, San Francisco, CA, USA.
Background: Lifestyle and metabolic multi-domain approaches targeting several risk factors at a time are increasingly being recognized as critical for dementia prevention since single-factor approaches and one-size-fits-all interventions often fall short in substantially reducing the dementia burden. Therefore, we compared the effectiveness of several hypothetical midlife lifestyle interventions considered singly and in combination across two health approaches: high-risk subpopulations (targeted) and general population (untargeted).
Method: Data came from the combined 2006 and 2008 biomarker samples of the Health and Retirement Study (HRS, N = 12,219).
Kardiochir Torakochirurgia Pol
December 2024
Sinop Ataturk Public Hospital Thoracic Surgery, Sinop, Turkey.
Unlabelled: Introduction Smoking cessation remains a global challenge due to the complex and individualized nature of addiction. Understanding the interplay of psychological, social, and biological factors is crucial for developing effective, personalized cessation strategies.
Aim: This study investigated the factors influencing the success of smoking cessation efforts among patients visiting thoracic surgery outpatient clinics.
Cureus
December 2024
Department of Surgery, Faculty of Medicine and Health Science, Sana'a University, Sana'a, YEM.
Introduction Anastomotic leakage (AL) following stoma closure is a significant complication that can lead to increased morbidity and mortality. Identifying risk factors associated with AL is essential for improving surgical outcomes, especially in resource-limited settings like Yemen. Methods We conducted this retrospective study at Al-Thawra Modern General Hospital and the Republican Teaching Hospital Authority in Sana'a, Yemen, between August 2020 and April 2024.
View Article and Find Full Text PDFNicotine Tob Res
January 2025
Professor and Director of Center for Neurobehavioral Research on Addiction, Louis A. Faillace, M.D., Department of Psychiatry and Behavioral Sciences, UTHealth, McGovern Medical School, 1941 East Road, BBSB, Houston, TX.
Introduction: Understanding predictors of smoking cessation medication efficacy facilitates the ability to enhance treatment effectiveness. In our pilot trial, exenatide, a glucagon-like peptide-1 receptor agonist, adjunct to nicotine patch improved smoking abstinence compared to nicotine patch alone. This secondary analysis explores potential baseline characteristics associated with differential treatment response to exenatide.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!